Hookipa Pharma Inc (HOOK) Stock Price, Quote & News

Company Profile

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of...

Industry: Biotechnology

Sector: Healthcare

Phone: 431 890 6360

Website: www.hookipapharma.com

Address:

350 Fifth Avenue, 72nd Floor Suite 7240, New York, United States

joe77w Apr. 3 at 2:10 PM

$HOOK 2025 ANNUAL REPORT OUT, LINK https://www.otcmarkets.com/file/company/financial-report/547261/content

0 · Reply

joe77w Apr. 3 at 2:09 PM

$HOOK free money here, absurd undervaluation or am I wrong? How Is It possible co to liquidate 1.28/1.71 USD when updated cash position/net equity do imply + 2 USD per shareholder even assuming liquidation and dissolution costs, potential indeminifications and tax liabilities? https://www.otcmarkets.com/file/company/financial-report/547261/content Take a look at balance sheets, 32 mln USD in net equity as of december 31 + 5 mln USD from GILD + 5 mln USD from NEOTRAIL, should have raised net equity/cash available for distribution. Certificate of Dissolution should be filed in late april/early May, then stock delisted from OTC because transfer agent will close books. Am I wrong or market Is underestimating future cash proceeds? NeoTrail bought asset for 5 mln USD, amount disclosed in the last sec filing, GILEAD completed 10 mln USD deal buying every agreed cent. I am assuming +- 14 mln fully diluted common shares. What Is wrong or am I right assuming liquidation North of 2 USD?

0 · Reply

koditrump Feb. 10 at 10:43 PM

$LYFT $HOOK $SCHW

0 · Reply

biovaluable Feb. 9 at 2:29 AM

$BCAB $BCAB $HOOK oh my god such a fuxx company!

0 · Reply

joe77w Feb. 7 at 6:41 PM

$HOOK https://www.otcmarkets.com/filing/html?id=18596713&guid=Aqt-keox_0xjJth

0 · Reply

joe77w Feb. 7 at 6:41 PM

$HOOK https://www.otcmarkets.com/file/company/financial-report/507979/content 30 mln in net equity as of September 30 with 12.2 mln shares would be worth 2.45 USD per share in book value. Then we should Add 7.4 mln USD net by GILEAD for assets purchase plus recents asset sale to Neotrail for undisclosed amount. I assume Dissolution and liquidation costs plus some cash burn should be around 12 mln USD with 25 mln USD left to be liquidated to shareholders when and If certificate of Dissolution filed to Delaware SOS... 25 mln /12.2 shares gives me more than 2 USD per share but according most recent meeting to vote Dissolution liquidation value beetwen 1.28 and 1.72 USD per share, what Is wrong? I would assume 1.72 at least if not more... What if bod decides not to file for Dissolution but seeking a merger , there Is a small chance Dissolution cancelled and operations to resume. I find stock very cheap, a Shell with cash and equity without debt or positive equity around 25/30 mln

0 · Reply

dinnerwithme Feb. 6 at 4:47 AM

$BCAB $BCAB The company's strategy for maintaining its listing has never been successful. Fact check! 1. Maintain MVLS -> Failure (Nasdaq Disapproval) 2. BP partnership -> Failure (only inversagen AI deal) 3. bid compliance -> Failure (until 2/2) 4. PPA induces high stock conversion(11/26) -> failure, Yorkville maybe exit at Dec, Jan. 5. Issuance of Super Voting Rights -> Failure (Nasdaq Disapproval) 6. RS Strategy -> Failed twice 7. cash -> burning state 8. equity -> Only numbers are resolved through a joint venture from a company related to the representative(invergagen AI). deposit is unknown or secured) 9. Reverse merger -> ???? maybe f..... All that remains is liquidation or delisting. However, after liquidation, the cost for liquidation of creditors and executives and employees comes first. There is no shareholder's share. like $HOOK

0 · Reply

joe77w Feb. 6 at 2:39 AM

$HOOK I would expect liquidation to happen at higher range around 1,71 USD given co.completed asset sale to GILEAD and now NEOTRAIL, its a matter of patience. I dont see any downside but only upside, strange pps does not hit 1,28 USD the minimum liquidation value. Holding tight my shares. Do your due diligence before investing your Money. This Is not a financial advice.

0 · Reply

joe77w Feb. 6 at 2:34 AM

$HOOK new asset sale https://www.nasdaq.com/articles/hookipa-pharma-t0-sell-oncology-assets-hb-200-and-hb-700-neotrail-therapeutics

0 · Reply

joe77w Feb. 6 at 12:11 AM

$HOOK new asset sale just happened, bullish view about liquidation value, 1,65 the minimum Just my opinion.

0 · Reply

HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics

Oct 31, 2025, 8:00 AM EDT - 5 months ago

HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead

Jul 18, 2025, 4:05 PM EDT - 9 months ago

HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock

Feb 20, 2025, 3:06 PM EST - 1 year ago

HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)

Jan 10, 2025, 2:00 AM EST - 1 year ago

Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA

Jan 8, 2025, 11:23 AM EST - 1 year ago

HOOKIPA Pharma Inc - FORM 8 (OPD)

Jan 7, 2025, 4:05 PM EST - 1 year ago

HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

Jan 6, 2025, 2:00 AM EST - 1 year ago

HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment

Jan 2, 2025, 2:00 AM EST - 1 year ago

Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.

Nov 11, 2024, 4:05 PM EST - 1 year ago

HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker

Oct 31, 2024, 9:17 AM EDT - 1 year ago

HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024

Oct 30, 2024, 7:30 AM EDT - 1 year ago

HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

Sep 24, 2024, 7:30 AM EDT - 1 year ago

HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm

Aug 30, 2024, 8:00 AM EDT - 1 year ago

HOOKIPA Pharma Announces Board of Directors Changes

Aug 28, 2024, 8:57 AM EDT - 1 year ago

HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:30 PM EDT - 1 year ago

HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jul 22, 2024, 8:30 AM EDT - 1 year ago

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

Jul 8, 2024, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split

Jul 1, 2024, 4:31 PM EDT - 1 year ago

HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV

Jun 4, 2024, 1:00 PM EDT - 1 year ago

HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

May 30, 2024, 4:30 PM EDT - 2 years ago

HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting

May 23, 2024, 5:01 PM EDT - 2 years ago

HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting

May 9, 2024, 7:01 AM EDT - 2 years ago

HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 25, 2024, 7:01 AM EDT - 2 years ago

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

Apr 24, 2024, 7:01 AM EDT - 2 years ago

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers

Apr 16, 2024, 4:30 PM EDT - 2 years ago

HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Apr 10, 2024, 7:01 AM EDT - 2 years ago

HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration

Mar 22, 2024, 7:01 AM EDT - 2 years ago

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Mar 6, 2024, 7:01 AM EST - 2 years ago

HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference

Jan 29, 2024, 8:01 AM EST - 2 years ago

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs

Jan 16, 2024, 7:01 AM EST - 2 years ago

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization

Dec 21, 2023, 7:01 AM EST - 2 years ago

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences

Nov 20, 2023, 7:01 AM EST - 2 years ago

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

Nov 9, 2023, 7:01 AM EST - 2 years ago

HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 3, 2023, 12:01 PM EDT - 2 years ago

HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023

Nov 2, 2023, 4:01 PM EDT - 2 years ago

HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023

Oct 22, 2023, 6:01 AM EDT - 2 years ago

HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023

Oct 18, 2023, 7:01 AM EDT - 2 years ago

HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences

Sep 13, 2023, 8:45 AM EDT - 2 years ago

HOOKIPA Announces Executive Leadership Change

Sep 12, 2023, 7:01 AM EDT - 2 years ago

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Sep 6, 2023, 7:01 AM EDT - 2 years ago

HOOKIPA Pharma to participate in upcoming investor conferences in September

Aug 10, 2023, 7:01 AM EDT - 2 years ago

HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 3, 2023, 7:01 AM EDT - 2 years ago

HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023

Jun 10, 2023, 5:00 AM EDT - 3 years ago

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

May 31, 2023, 9:30 PM EDT - 3 years ago

HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock

May 31, 2023, 4:45 PM EDT - 3 years ago

HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers

May 11, 2023, 7:01 AM EDT - 3 years ago

HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 9, 2023, 7:01 AM EDT - 3 years ago

HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B

May 4, 2023, 7:02 AM EDT - 3 years ago

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May

joe77w Apr. 3 at 2:10 PM

$HOOK 2025 ANNUAL REPORT OUT, LINK https://www.otcmarkets.com/file/company/financial-report/547261/content

0 · Reply

joe77w Apr. 3 at 2:09 PM

0 · Reply

koditrump Feb. 10 at 10:43 PM

$LYFT $HOOK $SCHW

0 · Reply

biovaluable Feb. 9 at 2:29 AM

$BCAB $BCAB $HOOK oh my god such a fuxx company!

0 · Reply

joe77w Feb. 7 at 6:41 PM

$HOOK https://www.otcmarkets.com/filing/html?id=18596713&guid=Aqt-keox_0xjJth

0 · Reply

joe77w Feb. 7 at 6:41 PM

0 · Reply

dinnerwithme Feb. 6 at 4:47 AM

0 · Reply

joe77w Feb. 6 at 2:39 AM

0 · Reply

joe77w Feb. 6 at 2:34 AM

$HOOK new asset sale https://www.nasdaq.com/articles/hookipa-pharma-t0-sell-oncology-assets-hb-200-and-hb-700-neotrail-therapeutics

0 · Reply

joe77w Feb. 6 at 12:11 AM

$HOOK new asset sale just happened, bullish view about liquidation value, 1,65 the minimum Just my opinion.

0 · Reply

pointnopoint Feb. 5 at 10:17 PM

$HOOK Does this still hold up?

0 · Reply

biovaluable Feb. 4 at 12:44 PM

$BCAB will move like $HOOK which delisted last year.

0 · Reply

Stock_Catcher Feb. 3 at 1:32 PM

$HOOK HOOK HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics

0 · Reply

contrarianinme Feb. 3 at 10:00 AM

$HOOK what is happening with this stock

0 · Reply

Popeye989 Oct. 14 at 3:16 PM

$HOOK another one bites the dust. So long from the watch list

0 · Reply

paulydestefano Oct. 7 at 1:37 AM

If PRHI can crack above key resistance, it may go vertical. The fundamentals are aligned with technicals: micro float, oversold zone, and huge upside range. Add a short squeeze into the mix and you’ve got a textbook 20–50× candidate. $IBG $MODD $AVTX $YOSH $HOOK

0 · Reply

KobeSetups Oct. 3 at 1:06 PM

If GIPR becomes the next REIT-crypto hybrid play, the re rate will be violent. Add in a micro float, real tenants, and a book value that’s completely ignored this could be the next legendary rerate ticker. Eyes on this before it headlines. $MNPR $THMO $LGVN $HOOK $PEV

0 · Reply

DataCenterTrader Sep. 26 at 11:25 PM

IVDA is a rare find: ✔️ Robotics ✔️ AI ✔️ Drones ✔️ Undervalued ✔️ At the exact bottom This isn’t just a low float trade this is a tech sleeper with real-world potential. One volume spike or news cycle, and it could go vertical. $NAOV $COSM $HOOK $AVTX $SNMP

0 · Reply

KobeSetups Sep. 7 at 8:34 PM

SKYQ is a deep sleeper with massive upside. 📈 Real revenue 🔋 Clean tech infrastructure 🧠 Blockchain expansion 🪙 Energy tokenization deal inked 💥 No dilution, low cap, and the chart is coiled This could wake up violently. $BFRG $HOOK $STSS $NAOV

0 · Reply

elmono Sep. 6 at 9:16 PM

$HOOK always right

0 · Reply

joe77w Aug. 26 at 7:40 PM

$HOOK Just because co. Was so plenty of cash and with very little liabilities, my humble opinion liquidation will happen at High end therefore around 1.6/1.7 USD Stock below only because on OTC, smart and professional investors with no restriction buying a lot

0 · Reply

joe77w Aug. 26 at 6:43 PM

$HOOK 15/21 mln available for DISTRIBUTION according sec filing or 1.28/1.72 USD, clearly stated, still trading at huge discount vs minimal liquidation estimated value https://www.otcmarkets.com/filing/html?id=18596713&guid=SBE-kW3a1BQFJth

0 · Reply

Market Cap	10.24M
Revenue (ttm)	43.95M
Net Income (ttm)	-43.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-98.98%
Debt to Equity Ratio	0.00

Volume	147,700
Avg Vol	112,680
Day's Range	N/A - N/A
Shares Out	12.19M
Stochastic %K	50%
Beta	0.93
Analysts	Hold
Price Target	$2.00